Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Tuesday 03 August, 2021

Feedback PLC

Digital Health article highlights Bleepa potential

RNS Number : 2811H
Feedback PLC
03 August 2021
 

RNS REACH

 

Feedback plc

 

Digital Health article highlights potential for Bleepa

 

· Digital Health webinar explores the clinical and regulatory risks of mobile messaging platforms

 

London, 03 August 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, has been featured in an article in Digital Health. 

 

The article raises legitimate concerns around security of mobile messaging platforms and discusses the worries of those in the industry wanting to use them.  "Mobile messaging systems are a vital tool to enable busy clinicians to manage heavy caseloads, but there is increasing concern about the clinical and regulatory risk to which some systems can expose users and their employers. A recent Digital Health webina r explored this topic and found that more than half of the 130 or so participants were concerned that the messaging platform they used for clinical work did not comply with GDPR. In addition, more than a third of participants were worried that decisions made using their messaging system did not link to their organisation's electronic patient record (EPR)."

 

For the full article, click here: https://www.digitalhealth.net/2021/07/mobile-messaging-platforms-the-clinical-and-regulatory-risks-explored/

 

Dr Tom Oakley, CEO of Feedback, added: "We are delighted to have been featured in Digital Health's article following an extremely insightful webinar which discussed the significant exposure to risk that Trusts and clinicians have when using unregulated devices and the pitfalls that mobile messaging platform must navigate to provide truly secure and safe systems for clinicians to use.  We understand that clinicians need a tool that allows them to complete their work in a compliant and secure way.  Bleepa is the forerunner in providing exactly these needs and applaud Digital Health's focus on the needs and safety of both clinicians and their patients alike. "

 

Tom Oakley joined Digital Health's highly successful webinar alongside Georges Ng Man Kwong, Consultant Chest Physician and Chief Clinical Information Officer at Pennine Acute Hospitals NHS Trust and Darryn Hale, Senior Associate, Beachcroft LLP, a healthcare information governance legal specialist, to discuss 'Safe, secure and compliant clinical messaging: lessons from the COVID-19 pandemic'.

 

For the Digital Health webinar highlights: https://youtu.be/w8NzEHowUUo

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0) 20 3997 7634

[email protected]



Allenby Capital Limited (Nominated Adviser)

David Worlidge / Vivek Bhardwaj

+44 (0)20 3328 5656



Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKBBKBBKDAFK

a d v e r t i s e m e n t